6 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 9 Phase 2, 5 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 4, Withdrawn 2, Completed 1, Terminated 1, Unknown 1 |
| Phase 1 | 5 | Active not recruiting 3, Completed 2 |
| Not applicable | 2 | Active not recruiting 1, Recruiting 1 |
Follow Stage IV Rectal Cancer AJCC v8: new trials by email Literature Review of Stage IV Rectal Cancer AJCC v8 trials Research Report on Stage IV Rectal Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Family Communications After Genetic Testing Biospecimen Collection, Genetic Testing, Communication Intervention - Colon Adenocarcinoma, Colorectal Adenocarcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 4186 | 2026-04-06 | 2026-10-02 |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events Best Practice, Patient Monitoring, Questionnaire Administration - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 750 | 2021-05-12 | 2026-06-16 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Genetic Testing - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Terminated | Academic and Community Cancer Research United | 199 | 2020-04-20 | 2025-08-29 | |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
| Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer Quality-of-Life Assessment, Questionnaire Administration - Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8 | Recruiting | M.D. Anderson Cancer Center | 430 | 2014-05-16 | 2026-08-31 | |
| Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer Biospecimen Collection - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Active not recruiting | M.D. Anderson Cancer Center | 341 | 2013-09-05 | 2026-09-18 |
Rectal Neoplasms (15) · Colonic Neoplasms (13) · Colorectal Neoplasms (10) · Carcinoma, Hepatocellular (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Microsatellite Instability (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Digestive System Diseases (15) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Neoplasms (15) · Neoplasms by Site (15) · Rectal Diseases (15) · Gastrointestinal Neoplasms (14) · Colonic Diseases (13) · Colorectal Neoplasms (5) · Adenocarcinoma (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Nivolumab (3) · regorafenib (3) · Cetuximab (2) · Genetic Testing (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Trifluridine (2) · balstilimab (2) · trifluridine tipiracil drug combination (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Bevacizumab (1) · Biopsy (1) · CTLA-4 Antigen (1) · Disulfides (1)
M.D. Anderson Cancer Center (6) · Academic and Community Cancer Research United (3) · City of Hope Medical Center (3) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1)
United States (14) · Puerto Rico (2)
John H Strickler (4) · Marwan G Fakih (3) · Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Frank A Sinicrope (1) · George J Chang (1) · Ryan W Huey, MD (1) · Van K Morris (1) · Van K Morris, MD (1) · Yi-Qian N You (1)
PMID 33109741, PMID 36821818, PMID 36892833, PMID 39652198
P30CA015083 (3), P30CA033572 (2), K07CA133187 (1), R01CA187238 (1), U10CA180888 (1), UM1CA186704 (1)